- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Events 211 results
Webinar
июня 20, 2023
New Developments in Regulatory Review Requirements for Healthcare M&A Transactions
Webinar
июня 8, 2023
Are You Ready? The New FDA Requirement for Diversity Action Plans in Drug and Device Clinical Investigations
Webinar
мая 10, 2023
Talk im Turm – Parallel Import: ECJ Reboxing vs. Relabeling Decision
Webinar
апреля 20, 2023
Revision of the EU Pharmaceutical Legislation - What To Expect
Webinar
апреля 5, 2023
Restructuring Takeover – A Crash Course on Hot Topics in Healthcare Restructurings
Webinar
марта 15, 2023
What You Need to Know About the USITC Investigation into a TRIPS Waiver for COVID-19 Diagnostics and Therapeutics
Webinar
марта 13, 2023
Key Food and Beverage Issues: Challenges and Opportunities in 2023
Webinar
февраля 23, 2023
MDLs: Judges, Defendants and Plaintiffs Too – Who Is Buzzing About What?
Webinar
февраля 15, 2023
Healthcare Fraud Enforcement Update - What Does 2023 Hold?
Webinar
января 31, 2023
Best Practices for UK & EU Fund Managers Raising Capital in the GCC
Webinar
января 24, 2023
Year in Review for Drug and Device Advertising and Promotion: Lessons Learned From 2022 FDA Enforcement Letters and Other Key Developments
Webinar
января 19, 2023
A New Year, A New Day - What’s Next for Healthcare Policy and Oversight in the New Congress